# Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)

> **NCT01553786** · PHASE2 · COMPLETED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 80 (actual)

## Conditions studied

- T-cell Lymphoma

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01553786
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2018-03
- **Final completion:** 2019-03-21
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2021-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01553786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01553786, "Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01553786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*